Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.01 USD
Change Today +0.06 / 2.03%
Volume 79.1K
BTX On Other Exchanges
BTX is not on other exchanges.
As of 1:42 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

biotime inc (BTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $5.95
52 Week Low
08/24/15 - $2.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOTIME INC (BTX)

biotime inc (BTX) Related Businessweek News

No Related Businessweek News Found

biotime inc (BTX) Details

BioTime, Inc., a biotechnology company, engages in the research and product development in the field of regenerative medicine. The company focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including PureStem human embryonic progenitor cell lines; associated ESpan culture media; human embryonic stem cell lines; HyStem hydrogel products; and Hextend, a blood plasma volume expander for hypovolemia in surgery, emergency trauma, and other applications. The company’s clinical programs include OpRegen and OpRegen-Plus, which are in Phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1 that is in Phase I/IIa trial for spinal cord injuries; Renevia, which is in pivotal trial for HIV-related lipoatrophy; and AST-VAC2 that is in pre-clinical stage for non-small cell lung cancer. It is also developing Premvia, a hydrogel formulation of cross-linked thiol-modified hyaluronan and thiol-modified gelatin to manage wounds; ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and PanC-Dx, a diagnostic product used to detect breast, bladder, and lung cancers, as well as mobile health software products. In addition, the company markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; VarElect, an application for prioritizing gene variants; and MalaCards, a database of human diseases, as well as analysis tools. Further, it develops cell based therapeutic products for diseases, such as neurological, cancer, age related macular degeneration, orthopedic, and age-related cardiovascular diseases. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

117 Employees
Last Reported Date: 03/11/15
Founded in 1990

biotime inc (BTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $884.3K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $537.6K
Chief Operating Officer
Total Annual Compensation: $5.2K
Chief Executive Officer of Asterias Biotherap...
Total Annual Compensation: $224.4K
Compensation as of Fiscal Year 2014.

biotime inc (BTX) Key Developments

BioTime, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015

BioTime, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $2,009,000, loss from operations of $13,496,000, loss before income tax benefit of $13,267,000, net loss attributable to company common shareholders of $9,743,000 or $0.12 per basic and diluted share compared to the total revenues of $1,107,000, loss from operations of $13,062,000, loss before income tax benefit of $12,907,000, net loss attributable to company common shareholders of $9,554,000 or $0.16 per basic and diluted share for the same quarter a year ago. For the six months period, the company reported total revenues of $3,268,000, loss from operations of $27,005,000, loss before income tax benefit of $27,049,000, net loss attributable to company common shareholders of $19,917,000 or $0.25 per basic and diluted share compared to the total revenues of $2,173,000, loss from operations of $24,183,000, loss before income tax benefit of $23,967,000, net loss attributable to company common shareholders of $17,643,000 or $0.29 per basic and diluted share for the same period a year ago.

BioTime, Inc., Annual General Meeting, Jul 10, 2015

BioTime, Inc., Annual General Meeting, Jul 10, 2015., at 10:30 US Eastern Standard Time. Location: 1221 Avenue of the Americas. Agenda: To elect ten directors to hold office until the next annual meeting of shareholders and until their respective successors are duly elected and qualified; to ratify the appointment of OUM & Co. LLP as the company's independent registered public accountants for the fiscal year ending December 31, 2015; to approve certain amendments to the BioTime Equity Incentive Plan; to hold an advisory vote on executive compensation; and to transact such other business as may properly come before the meeting or any adjournments of the meeting.

BioTime, Inc. and OncoCyte Corporation Announce Positive Interim Results from Lung Cancer Study

BioTime, Inc. and OncoCyte Corporation have announced positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed samples of a simple blood-based test designed for the early detection of lung cancer. The large, prospective clinical study was conducted by The Wistar Institute. The test was developed in the laboratory of Louise Showe, PhD, professor in the Molecular and Cellular Oncogenesis program of The Wistar Institute's NCI-designated cancer center. As part of the study, clinical investigators used a simple collection system that is approved by the FDA to prepare over 600 peripheral blood samples from patients determined to be at high risk for developing lung cancer based on age and smoking history. These patients were undergoing either low-dose computed tomography (CT) scanning for lung cancer or were recently diagnosed with lung cancer. Wistar scientists then assessed the expression of messenger RNA and micro RNA in the initial training set of 242 samples and developed a classifier of 145 markers (125 mRNAs plus 20 micro RNAs) that most accurately distinguished patients with malignant nodules from those with benign or no findings. The classifier was then assessed in an independent test set of 103 samples. Performance of the classifier was evaluated using several criteria, including Receiver Operating Characteristic (ROC) area under the curve (AUC) analysis, and yielded an AUC of 0.88 (sensitivity of 76% with a specificity of 88%) in the test set. Analysis of the full patient sample set is near completion. In October 2013, OncoCyte entered into a Sponsored Research Agreement with The Wistar Institute to identify, develop and test potential lung cancer biomarkers collaboratively with Dr. Showe's laboratory. OncoCyte has exercised options to obtain exclusive licenses to any inventions, discoveries or technology developed in the course of the collaborative research, including the technology presented and expects to negotiate definitive license agreements with Wistar.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTX:US $3.01 USD +0.06

BTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Neuralstem Inc $1.60 USD +0.12
Ocata Therapeutics Inc $3.62 USD -0.15
Organovo Holdings Inc $2.49 USD -0.01
ReNeuron Group PLC 5.38 GBp 0.00
ReproCELL Inc ¥529.00 JPY +23.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.0x
Price/Book 16.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at